Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1). FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 51.00 | |
10 mg | In stock | $ 84.00 | |
25 mg | In stock | $ 172.00 | |
50 mg | In stock | $ 278.00 | |
100 mg | In stock | $ 418.00 | |
500 mg | In stock | $ 988.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 57.00 |
Description | FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1). FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses. |
Targets&IC50 | HSV1:0.69 μM, CDK9-CyclinT1:5.8 μM |
In vitro | FIT-039 inhibits HPV replication and expression of E6 and E7 viral oncogenes, restoring tumor suppressors p53 and pRb in HPV+?cervical cancer cells. The therapeutic effect of FIT-039 was demonstrated in CIN model of an organotypic raft culture, where FIT-039 suppressed HPV18-induced dysplasia/hyperproliferation with reduction in viral load. FIT-039 also repressed growth of HPV16+, but not HPV-?cervical cancer xenografts without any significant adverse effects. Safety and pharmacokinetics of FIT-039 were confirmed for systemic and topical routes[1]. |
Cell Research | Examined FIT-039 for its effect on HPV gene expression in HPV+ cervical cancer cells.?Primary keratinocytes monolayer and organotypic raft culture models were used to evaluate HPV viral replication and cervical intraepithelial neoplasia (CIN) phenotypes.?Preclinical pharmacokinetics and toxicity tests for FIT-039 were also conducted.?Finally, the anti-HPV effect of FIT-039 was further examined in vivo, using HPV+ cervical cancer xenografts[1] |
Molecular Weight | 315.41 |
Formula | C17H18FN3S |
CAS No. | 1113044-49-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (95.11 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FIT-039 1113044-49-7 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Others DNA/RNA Synthesis CDK HSV Cytomegalovirus HSV-1 Herpes simplex virus transcription FIT 039 Inhibitor DNA Cyclin dependent kinase CDK9 CMV mRNA FIT039 viruses antiviral inhibit orally polymerase-II HSV-2 inhibitor